Heterosexual AIDS Cases Up Sharply, But Numbers Remain Small

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

BETHESDA, Md--As expected, the number of reported AIDS cases increased substantially in 1993 due to the expansion of the surveillance case definition in January of that year, but an adjusted analysis shows only a slight overall increase.

BETHESDA, Md--As expected, the number of reported AIDS cases increasedsubstantially in 1993 due to the expansion of the surveillancecase definition in January of that year, but an adjusted analysisshows only a slight overall increase.

This analysis showed a 1993 incidence increase of 3% (62,000 casesin 1993 versus 60,000 in 1992). However, a slight decrease (1%)was seen in homosexual/bisexual men, while the AIDS incidencefor intravenous drug users increased by 8%, and for heterosexualsby 23% (MMWR 43:826-831, 1994).

Still, the number of persons infected through heterosexual contactremains small (7,500 in 1993), compared with the number infectedthrough homosexual sex (30,300) or IV drug use (17,800).

The report also showed significant geographic differences in AIDSincidence trends. Although the number of cases contracted throughheterosexual sex rose in all four regions of the country, theincreases varied widely, from 11% in the South to 39% in the Northeast.

The incidence among IV drug users increased in the Northeast,where most lived when diagnosed, but remained stable in the Southand West. The number of homosexual cases decreased in the Westwhile remaining stable in the Northeast, South, and Midwest.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content